Achondroplasia: Pathogenesis and implications for future treatment

Current Opinion in Pediatrics

Volumn 22, Issue 4, 2010, Pages 516-523

  Laederich, Melanie B ^a   Horton, William A ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

achondroplasia; c type natriuretic peptide; endochondral ossification; FGFR3; Fibroblast Growth Factor Receptor 3; growth plate; targeted therapies

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; NATRIURETIC PEPTIDE TYPE C; NEUTRALIZING ANTIBODY; PHOSPHOTRANSFERASE INHIBITOR; RECOMBINANT NATRIURETIC PEPTIDE TYPE C 22; STAT PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG; FGFR3 PROTEIN, HUMAN; NATRIURETIC FACTOR;

ACHONDROPLASIA; ALLELE; BINDING AFFINITY; CARTILAGE; DOSE RESPONSE; ENCHONDRAL OSSIFICATION; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GROWTH PLATE; HUMAN; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; RESEARCH; REVIEW; SAFETY; SIGNAL TRANSDUCTION; ANIMAL; GENETIC PREDISPOSITION; GENETICS; MUTATION; PROGNOSIS;

ACHONDROPLASIA; ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, C-TYPE; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3;

EID: 77955228906     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32833b7a69     Document Type: Review

References (70)

1. Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet 2007; 370:162-172.
2. Velinov M, Slaugenhaupt SA, Stoilov I, et al. The gene for achondroplasia maps to the telomeric region of chromosome 4p. Nat Genet 1994; 6:314-317.
3. Shiang R, Thompson LM, Zhu YZ, et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 1994; 78:335-342.
4. Bellus GA, Hefferon TW, Ortiz de Luna RI, et al. Achondroplasia is defined by recurrent G380R mutations of FGFR3. Am J Hum Genet 1995; 56:368-373.
5. Rousseau F, Bonaventure J, Legeai-Mallet L, et al. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 1994;371:252-254.
6. Tavormina PL, Shiang R, Thompson LM, et al. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet 1995; 9:321-328.
7. Bellus GA, McIntosh I, Smith EA, et al. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. Nat Genet 1995; 10:357-359.
8. Colvin JS, Bohne BA, Harding GW, et al. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet 1996; 12:390-397.
9. Deng C, Wynshaw-Boris A, Zhou F, et al. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 1996; 84:911-921.
10. Naski MC, Colvin JS, Coffin JD, Ornitz DM. Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development 1998; 125:4977-4988.
11. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16:139-149.
12. Ornitz DM. FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev 2005; 16:205-213.
13. Chen H, Ma J, Li W, et al. A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol Cell 2007; 27:717-730.
14. Itoh N, Ornitz DM. Functional evolutionary history of the mouse Fgf gene family. Dev Dyn 2008; 237:18-27.
15. Ornitz DM, Xu J, Colvin JS, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996; 271:15292-15297.
16. Liu Z, Xu J, Colvin JS, Ornitz DM. Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18. Genes Dev 2002; 16:859-869.
17. Ohbayashi N, Shibayama M, Kurotaki Y, et al. FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. Genes Dev 2002; 16:870-879.
18. Plotnikov AN, Schlessinger J, Hubbard SR, Mohammadi M. Structural basis for FGF receptor dimerization and activation. Cell 1999; 98:641-650.
19. Hart KC, Robertson SC, Donoghue DJ. Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation. Mol Biol Cell 2001; 12:931-942.
20. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 2005; 16:107-137.
21. Horton WA, Degnin CR. FGFs in endochondral skeletal development. Trends Endocrinol Metab 2009; 20:341-348.
22. Su WC, Kitagawa M, Xue N, et al. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature 1997; 386:288-292.
23. Legeai-Mallet L, Benoist-Lasselin C, Delezoide AL, et al. Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia. J Biol Chem 1998; 273:13007-13014.
24. Sahni M, Ambrosetti DC, Mansukhani A, et al. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev 1999; 13:1361-1366.
25. Hart KC, Robertson SC, Kanemitsu MY, et al. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 2000;19:3309-3320.
26. Choi DY, Toledo-Aral JJ, Lin HY, et al. Fibroblast growth factor receptor 3 induces gene expression primarily through Ras-independent signal transduction pathways. J Biol Chem 2001; 276:5116-5122.
27. Murakami S, Balmes G, McKinney S, et al. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Genes Dev 2004; 18:290-305.
28. Zhang R, Murakami S, Coustry F, et al. Constitutive activation of MKK6 in chondrocytes of transgenic mice inhibits proliferation and delays endochondral bone formation. Proc Natl Acad Sci U S A 2006; 103:365-370.
29. Minina E, Kreschel C, Naski MC, et al. Interaction of FGF, Ihh/Pthlh, and BMP signaling integrates chondrocyte proliferation and hypertrophic differentiation. Dev Cell 2002; 3:439-449.
30. Minina E, Wenzel HM, Kreschel C, et al. BMP and Ihh/PTHrP signaling interact to coordinate chondrocyte proliferation and differentiation. Development 2001; 128:4523-4534.
31. Dailey L, Laplantine E, Priore R, Basilico C. A network of transcriptional and signaling events is activated by FGF to induce chondrocyte growth arrest and differentiation. J Cell Biol 2003; 161:1053-1066.
32. Horton WA. Skeletal Development. In: Unsicker K, Krieglstein K, editors. Cell signaling and growth factors in development. Weinheim: Wiley-VCH; 2006. pp. 619-640.
33. Webster MK, Donoghue DJ. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J 1996; 15:520-527.
34. You M, Li E, Hristova K. The achondroplasia mutation does not alter the dimerization energetics of the fibroblast growth factor receptor 3 transmembrane domain. Biochemistry 2006; 45:5551-5556.
35. Monsonego-Ornan E, Adar R, Feferman T, et al. The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation. Mol Cell Biol 2000; 20:516-522.
36. Cho JY, Guo C, Torello M, et al. Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. Proc Natl Acad Sci U S A 2004; 101:609-614.
37. Guo C, Degnin CR, Laederich MB, et al. Sprouty 2 disturbs FGFR3 degradation in thanatophoric dysplasia type II: a severe form of human achondroplasia. Cell Signal 2008; 20:1471-1477.
38. Ben-Zvi T, Yayon A, Gertler A, Monsonego-Ornan E. Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and modulate fibroblast growth factor receptor signaling. J Cell Sci 2006; 119:380-387.
39. Horton WA. Skeletal development: insights from targeting the mouse genome. Lancet 2003; 362:560-569.
40. Kronenberg HM. Developmental regulation of the growth plate. Nature 2003; 423:332-336.
41. Dailey L, Ambrosetti D, Mansukhani A, Basilico C. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 2005; 16:233-247.
42. Murakami S, Kan M, McKeehan WL, de Crombrugghe B. Up-regulation of the chondrogenic Sox9 gene by fibroblast growth factors is mediated by the mitogen-activated protein kinase pathway. Proc Natl Acad Sci U S A 2000; 97:1113-1118.
43. Kratz CP, Zampino G, Kriek M, et al. Craniosynostosis in patients with Noonan syndrome caused by germline KRAS mutations. Am J Med Genet A 2009; 149A:1036-1040.
44. Tidyman WE, Rauen KA. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev 2009; 19:230-236.
45. Yasoda A, Komatsu Y, Chusho H, et al. Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat Med 2004; 10:80-86.
46. Chusho H, Tamura N, Ogawa Y, et al. Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci U S A 2001; 98:4016-4021.
47. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 2006; 27:47-72.
48. Miyazawa T, Ogawa Y, Chusho H, et al. Cyclic GMP-dependent protein kinase II plays a critical role in C-type natriuretic peptide-mediated endochondral ossification. Endocrinology 2002; 143:3604-3610.
49. Krejci P, Masri B, Fontaine V, et al. Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. J Cell Sci 2005; 118:5089-5100.
50. Yasoda A, Ogawa Y, Suda M, et al. Natriuretic peptide regulation of endochondral ossification. Evidence for possible roles of the C-type natriuretic peptide/guanylyl cyclase-B pathway. J Biol Chem 1998; 273:11695-11700.
51. Bartels CF, Bukulmez H, Padayatti P, et al. Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am J Hum Genet 2004; 75:27-34.
52. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009; 10:470-481.
53. Aviezer D, Golembo M, Yayon A. Fibroblast growth factor receptor-3 as a therapeutic target for Achondroplasia-genetic short limbed dwarfism. Curr Drug Targets 2003; 4:353-365.
54. Hall PS, Cameron DA. Current perspective-trastuzumab. Eur J Cancer 2009; 45:12-18.
55. Rauchenberger R, Borges E, Thomassen-Wolf E, et al. Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3. J Biol Chem 2003; 278:38194-38205.
56. Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999; 23:18-20.
57. Martinez-Torrecuadrada J, Cifuentes G, Lopez-Serra P, et al. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human singlechain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res 2005; 11:6280-6290.
58. Qing J, Du X, Chen Y, et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest 2009; 119:1216-1229.
59. Hadari Y, Schlessinger J. FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma. J Clin Invest 2009; 119:1077-1079.
60. Suda M, Ogawa Y, Tanaka K, et al. Skeletal overgrowth in transgenic mice that overexpress brain natriuretic peptide. Proc Natl Acad Sci U S A 1998; 95:2337-2342.
61. Kake T, Kitamura H, Adachi Y, et al. Chronically elevated plasma C-type natriuretic peptide level stimulates skeletal growth in transgenic mice. Am J Physiol Endocrinol Metab 2009; 297:E1339-E1348.
62. Yasoda A, Kitamura H, Fujii T, et al. Systemic administration of C-type natriuretic peptide as a novel therapeutic strategy for skeletal dysplasias. Endocrinology 2009; 150:3138-3144.
63. Hunt PJ, Richards AM, Espiner EA, et al. Bioactivity and metabolism of C-type natriuretic peptide in normal man. J Clin Endocrinol Metab 1994; 78:1428-1435.
64. Lee CY, Chen HH, Lisy O, et al. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol 2009; 49:668-673.
65. Shukla V, Coumoul X, Wang RH, et al. RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis. Nat Genet 2007; 39:1145-1150.
66. Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 2006; 24: 21-44.
67. Goldberg M, Langer R, Jia X. Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Ed 2007; 18:241-268.
68. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008; 5:505-515.
69. Rothenfluh DA, Bermudez H, O'Neil CP, Hubbell JA. Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage. Nat Mater 2008; 7:248-254.
70. Morris NP, Keene DR, Horton WA. Morphology and chemical composition of connective tissue: cartilage. In: Royce PM, Steinmann B, editors. Connective tissue and its heritable disorders. 2nd ed. New York: Wiley; 2002. pp. 41-66.